Damora Therapeutics, Inc. (DMRA) Stock
Damora Therapeutics stock price chart
DMRA stock quote & key statistics
Damora Therapeutics annual financials
Income statement →| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $0 | -$209.8M | -$4.57 |
| FY2024 | $0 | -$21.4M | -$18.61 |
| FY2023 | $0 | -$38.3M | -$33.86 |
| FY2022 | $0 | -$61.6M | -$60.76 |
| FY2021 | $0 | -$51.8M | -$51.25 |
Fiscal year ending December 31. Source: company filings via EODHD.
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Damora Therapeutics stock FAQ
What is the Damora Therapeutics stock ticker symbol?
Damora Therapeutics, Inc. trades on the NASDAQ under the ticker symbol DMRA.
What sector and industry is Damora Therapeutics in?
Damora Therapeutics, Inc. is classified in the Healthcare sector, Biotechnology industry.
How many employees does Damora Therapeutics have?
Damora Therapeutics, Inc. has about 7 full-time employees.
What were Damora Therapeutics's revenue and earnings last fiscal year?
Damora Therapeutics reported revenue of $0 and net income of -$209.8M in fiscal 2025, with earnings per share of -$4.57.
Is Damora Therapeutics in the Russell 2000?
Yes. Damora Therapeutics, Inc. (DMRA) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.
When did Damora Therapeutics go public?
Damora Therapeutics stock began trading on March 10, 2026.
Russell 2000 Biotechnology stocks
All Russell 2000 →- CGONCG Oncology
- COGTCogent Biosciences
- CRSPCRISPR Therapeutics
- CYTKCytokinetics
- DFTXDefinium Therapeutics
- DNTHDianthus Therapeutics
- IBRXImmunityBio
- IOVAIovance Biotherapeutics
- KODKodiak Sciences
- KRYSKrystal Biotech
- KYMRKymera Therapeutics
- LGNDLigand Pharmaceuticals
- MIRMMirum Pharmaceuticals
- ORKAOruka Therapeutics
- PCVXVaxcyte
- PRAXPraxis Precision Medicines
- PTCTPTC Therapeutics
- PTGXProtagonist Therapeutics
- RYTMRhythm Pharmaceuticals
- SRRKScholar Rock
- SYRESpyre Therapeutics
- TGTXTG Therapeutics
- TVTXTravere Therapeutics
- TWSTTwist Bioscience